 price
right multipl management track
evrisi thesi updat share write
thisbefor get debat valu share
let get fundament way core revenue perform
in-line yet anoth oper margin beat provid
cheer holder thought oper revenue guidanc
realli strong comp get tougher impli acceler
deliveri said today move entir tie disclosur
initi investig account practic
relat record fx hedg gain lot unknown
unfortun manag hand tie
commun fx hedg gain amount mm
cumul past year record incorrectli
dont know whether gain need back possibl
even increas even zero gain ep
impact manag annual
main question gotten whether could lead
restat part whether
preclud repurchas share posit side
impact line item oper remain
track els would odd guid margin
comment ep share count scenario like
think multipl premium associ execut
track record like come believ could trade
like near term price-to-earnings multipl reflect
msd organ dd ep profil given view lower
pt equat price-to-earnings cours
ep move target subject account audit result impact
move pension liabil prud
like
like
top-line c/c growth give confid fy outlook
guid impress
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
fy guidanc updat
guid look like reiter c/c sale growth om full year
recap prior fy guidanc
oper sale growth segment
renal
pharmaceut msd increas oper basi brevi expect declin
adj incom
om
renal continu driven increas patient volume pd product off-set lower sale hd
impact mm inventori revaclear dialyz
work w/ american kidney associ continu expand home dialysi
return solid constant currenc growth global
growth benefit uptak version pump iq infus system us
continu build pump platform long-term effort creat stabl segment
driven sale multi-chamb bag ou
also support micronutri
us well advanc plan place introduc market
gener inject servic off-set lower anesthesia sale well brevibloc
recent launch insulin product
hemostat sealant drove growth
benefit mm competit suppli constraint
competit suppli constraint expect contribut level
prismax well-receiv us far
gm strong top-lin perform mfg varianc off-set dialyz constraint
 focu still adjac cheaper make equal amount sens
sg reinvest busi support initi new product develop
valuat methodolog base mix discount cash flow analysi rel valuat multipl
increas competit price pressur fluid system fda qualiti issu tax reform uncertainti inabl
articl articl
time dissemin octob
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
